{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T02:15:36Z","timestamp":1788056136135,"version":"build-2784847793"},"reference-count":38,"publisher":"Royal College of Psychiatrists","issue":"2","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["cambridge.org"],"crossmark-restriction":true},"short-container-title":["BJPsych open"],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:sec id=\"S2056472423006075_sec_a1\">\n\t    <jats:title>Background<\/jats:title>\n\t    <jats:p>The frequent prescribing of psychotropics and high prevalence of polypharmacy among older adults with intellectual disabilities require close monitoring.<\/jats:p>\n\t  <\/jats:sec>\n\t  <jats:sec id=\"S2056472423006075_sec_a2\">\n\t    <jats:title>Aims<\/jats:title>\n\t    <jats:p>To describe change in prevalence, predictors and health outcomes of psychotropic use during the four waves (2009\/2010, 2013\/2014, 2016\/2017, 2019\/2020) of the Intellectual Disability Supplement to the Irish Longitudinal Study on Ageing (IDS-TILDA).<\/jats:p>\n\t  <\/jats:sec>\n\t  <jats:sec id=\"S2056472423006075_sec_a3\" sec-type=\"methods\">\n\t    <jats:title>Method<\/jats:title>\n\t    <jats:p>Eligible participants were adults (\u226540 years) with intellectual disabilities who participated in all four waves of IDS-TILDA and who reported medication use for the entire period. Differences between groups were tested using Cochran's <jats:italic>Q<\/jats:italic> test for binary variables and the McNemar\u2013Bowker test for variables with more than two categories. Generalised estimating equation models were used to assess associations between psychotropic use, participants\u2019 characteristics and health outcomes.<\/jats:p>\n\t  <\/jats:sec>\n\t  <jats:sec id=\"S2056472423006075_sec_a4\" sec-type=\"results\">\n\t    <jats:title>Results<\/jats:title>\n\t    <jats:p>Across waves (433 participants) there were no significant differences in prevalence of psychotropic use (61.2\u201364.2%) and psychotropic polypharmacy (42.7\u201338.3%). Antipsychotics were the most used subgroup, without significant change in prevalence between waves (47.6\u201344.6%). A significant decrease was observed for anxiolytics (26.8\u201317.6%; <jats:italic>P<\/jats:italic> &lt; 0.001) and hypnotics\/sedatives (14.1\u20139.0%; <jats:italic>P<\/jats:italic> &lt; 0.05). A significant increase was recorded for antidepressants (28.6\u201335.8%; <jats:italic>P<\/jats:italic> &lt; 0.001) and mood-stabilising agents (11.5\u201314.6%; <jats:italic>P<\/jats:italic> &lt; 0.05). Psychotropic polypharmacy (\u22652 psychotropics) was significantly associated with moderate to total dependence in performing activities of daily living over the 10-year period (OR = 1.80, 95% CI 1.21\u20132.69; <jats:italic>P<\/jats:italic> &lt; 0.05).<\/jats:p>\n\t  <\/jats:sec>\n\t  <jats:sec id=\"S2056472423006075_sec_a5\" sec-type=\"conclusions\">\n\t    <jats:title>Conclusions<\/jats:title>\n\t    <jats:p>The study indicates an increase in usage of some classes of psychotropic, a reduction in others and no change in the relatively high rate of antipsychotic use over 10 years in a cohort of older adults with intellectual disabilities and consequent risk of psychotropic polypharmacy and medication-related harm.<\/jats:p>\n\t  <\/jats:sec>","DOI":"10.1192\/bjo.2023.607","type":"journal-article","created":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T06:53:24Z","timestamp":1706770404000},"update-policy":"https:\/\/doi.org\/10.1017\/policypage","source":"Crossref","is-referenced-by-count":13,"title":["Psychotropic medicines\u2019 prevalence, patterns and effects on cognitive and physical function in older adults with intellectual disability in Ireland: longitudinal cohort study, 2009\u20132020"],"prefix":"10.1192","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3050-8361","authenticated-orcid":false,"given":"Marina","family":"Odalovi\u0107","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8524-2399","authenticated-orcid":false,"given":"Ashleigh","family":"Gorman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aviejay","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"McCallion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c9ilish","family":"Burke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malcolm","family":"MacLachlan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"McCarron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin C.","family":"Henman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maeve","family":"Moran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliette","family":"O'Connell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1183-6933","authenticated-orcid":false,"given":"Rohit","family":"Shankar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitriona","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e1ire","family":"O'Dwyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"170","published-online":{"date-parts":[[2024,2,1]]},"reference":[{"key":"S2056472423006075_ref1","doi-asserted-by":"crossref","first-page":"h4326","DOI":"10.1136\/bmj.h4326","article-title":"Mental illness, challenging behaviour, and psychotropic drug prescribing in people with intellectual disability: UK population based cohort study","volume":"351","author":"Sheehan","year":"2015","journal-title":"Br Med J"},{"key":"S2056472423006075_ref30","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1002\/gps.5518","article-title":"Long-term antidepressant use in a cohort of older people","volume":"36","author":"O'Neill","year":"2021","journal-title":"Int J Geriatr Psychiatry"},{"key":"S2056472423006075_ref13","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1192\/bjp.bp.115.173971","article-title":"Association of anticholinergic burden with adverse effects in older people with intellectual disabilities: an observational cross-sectional study","volume":"209","author":"O'Dwyer","year":"2016","journal-title":"Br J Psychiatry"},{"key":"S2056472423006075_ref22","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s41999-023-00786-x","article-title":"Psychotropic medication use and future unexplained and injurious falls and fracture amongst community-dwelling older people: data from TILDA","volume":"14","author":"Gallagher","year":"2023","journal-title":"Eur Geriatr Med"},{"key":"S2056472423006075_ref25","doi-asserted-by":"crossref","first-page":"e010861","DOI":"10.1136\/bmjopen-2015-010861","article-title":"Quetiapine use in adults in the community: a population-based study in Alberta, Canada","volume":"6","author":"Duncan","year":"2016","journal-title":"BMJ Open"},{"key":"S2056472423006075_ref23","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s40199-021-00390-z","article-title":"Surging trends in prescriptions and costs of antidepressants in England amid COVID-19","volume":"29","author":"Rabeea","year":"2021","journal-title":"Daru"},{"key":"S2056472423006075_ref34","unstructured":"34 Medicines Management Programme. Guidance on appropriate prescribing of benzodiazepines and z-drugs (BZRA) for the treatment of anxiety and insomnia. MMP, 2018 (https:\/\/www.drugsandalcohol.ie\/34248\/1\/guidance-on-appropriate-prescribing-of-bzra-feb-2021.pdf)."},{"key":"S2056472423006075_ref35","doi-asserted-by":"crossref","first-page":"e130","DOI":"10.1503\/cmaj.141219","article-title":"Effect of polypharmacy, potentially inappropriate medications and anticholinergic burden on clinical outcomes: a retrospective cohort study","volume":"187","author":"Lu","year":"2015","journal-title":"CMAJ"},{"key":"S2056472423006075_ref7","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1001\/jamainternmed.2019.1082","article-title":"Association between industry payments to physicians and gabapentinoid prescribing","volume":"179","author":"Rhee","year":"2019","journal-title":"JAMA Internal Med"},{"key":"S2056472423006075_ref9","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/imj.13671","article-title":"National disability insurance scheme, health, hospitals and adults with intellectual disability","volume":"48","author":"Wallace","year":"2018","journal-title":"Intern Med J"},{"key":"S2056472423006075_ref6","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1111\/jir.12773","article-title":"The association between medication use and gait in adults with intellectual disabilities","volume":"64","author":"Maas","year":"2020","journal-title":"J Intellect Disabil Res"},{"key":"S2056472423006075_ref14","doi-asserted-by":"crossref","first-page":"104197","DOI":"10.1016\/j.ridd.2022.104197","article-title":"Recruitment and retention in longitudinal studies of people with intellectual disability: a case study of the intellectual disability supplement to the Irish longitudinal study on ageing (IDS-TILDA)","volume":"124","author":"McCarron","year":"2022","journal-title":"Res Dev Disabil"},{"key":"S2056472423006075_ref29","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1192\/bjp.2022.34","article-title":"Antidepressant prescribing for adult people with an intellectual disability living in England","volume":"221","author":"Branford","year":"2022","journal-title":"Br J Psychiatry"},{"key":"S2056472423006075_ref28","doi-asserted-by":"crossref","first-page":"e036862","DOI":"10.1136\/bmjopen-2020-036862","article-title":"Changes over a decade in psychotropic prescribing for people with intellectual disabilities: prospective cohort study","volume":"10","author":"Henderson","year":"2020","journal-title":"BMJ Open"},{"key":"S2056472423006075_ref2","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1111\/jir.12391","article-title":"Prevalence, patterns and factors associated with psychotropic use in older adults with intellectual disabilities in Ireland","volume":"61","author":"O'Dwyer","year":"2017","journal-title":"J Intellect Disabil Res"},{"key":"S2056472423006075_ref24","doi-asserted-by":"crossref","first-page":"e006135","DOI":"10.1136\/bmjopen-2014-006135","article-title":"Prescribing of antipsychotics in UK primary care: a cohort study","volume":"4","author":"Marston","year":"2014","journal-title":"BMJ Open"},{"key":"S2056472423006075_ref4","doi-asserted-by":"crossref","DOI":"10.1177\/00048674221149864","article-title":"Use of psychotropic medications in adults with intellectual disability: a systematic review and meta-analysis","volume":"57","author":"Song","year":"2023","journal-title":"Aust N Z J Psychiatry"},{"key":"S2056472423006075_ref5","doi-asserted-by":"crossref","first-page":"e017406","DOI":"10.1136\/bmjopen-2017-017406","article-title":"Movement side effects of antipsychotic drugs in adults with and without intellectual disability: UK population-based cohort study","volume":"7","author":"Sheehan","year":"2017","journal-title":"BMJ Open"},{"key":"S2056472423006075_ref15","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3109\/09638288809164105","article-title":"The Barthel ADL Index: a standard measure of physical disability?","volume":"10","author":"Wade","year":"1988","journal-title":"Int Disabil Stud"},{"key":"S2056472423006075_ref32","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1111\/jir.12385","article-title":"Physicians\u2019 reasons not to discontinue long-term used off-label antipsychotic drugs in people with intellectual disability","volume":"61","author":"de Kuijper","year":"2017","journal-title":"J Intellect Disabil Res"},{"key":"S2056472423006075_ref33","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/bcp.12617","article-title":"Drugs with anticholinergic effects and cognitive impairment, falls and all-cause mortality in older adults","volume":"80","author":"Ruxton","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"S2056472423006075_ref20","volume-title":"R: A Language and Environment for Statistical Computing","year":"2022"},{"key":"S2056472423006075_ref27","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/jir.12685","article-title":"Psychotropic medication use in adults with intellectual disability in Queensland, Australia, from 1999 to 2015: a cohort study","volume":"64","author":"Song","year":"2020","journal-title":"J Intellect Disabil Res"},{"key":"S2056472423006075_ref26","unstructured":"26 McCarron, M , McCallion, P , Carroll, R , Burke, E , McGlinchey, E , O'Donovan, M-A , et al. Health, Wellbeing and Social Inclusion: Ageing with an Intellectual Disability in Ireland. The Intellectual Disability Supplement to The Irish Longitudinal Study on Ageing, 2017 (https:\/\/www.tcd.ie\/tcaid\/assets\/pdf\/wave3report.pdf)."},{"key":"S2056472423006075_ref31","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1192\/bjb.2021.72","article-title":"Prescribing antipsychotic medication for adults with intellectual disability: shared responsibilities between mental health services and primary care","volume":"46","author":"Paton","year":"2022","journal-title":"BJPsych Bull"},{"key":"S2056472423006075_ref10","doi-asserted-by":"crossref","DOI":"10.12688\/hrbopenres.13645.1","article-title":"Examining Quality, Use and Impact of Psychotropic (Use) in older adults with intellectual disabilities (EQUIP): study protocol [version 1; peer review: awaiting peer review]","volume":"5","author":"Gorman","year":"2022","journal-title":"HRB Open Res"},{"key":"S2056472423006075_ref16","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s12877-019-1190-3","article-title":"Association of Drug Burden Index with grip strength, timed up and go and Barthel Index activities of daily living in older adults with intellectual disabilities: an observational cross-sectional study","volume":"19","author":"O'Connell","year":"2019","journal-title":"BMC Geriatr"},{"key":"S2056472423006075_ref19","unstructured":"19 Carey, VJ , Lumley, TS , Moler, C , Ripley, B . Generalized Estimation Equation Solver: Version 4.13-26. RDocumentation\/CRAN, 2023 (https:\/\/cran.r-project.org\/web\/packages\/gee\/gee.pdf)."},{"key":"S2056472423006075_ref37","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/j.2051-5545.2009.tb00248.x","article-title":"International guide to prescribing psychotropic medication for the management of problem behaviours in adults with intellectual disabilities","volume":"8","author":"Deb","year":"2009","journal-title":"World Psychiatry"},{"key":"S2056472423006075_ref21","volume-title":"IBM SPSS Statistics for Window, Version 27.0. Released 2020"},{"key":"S2056472423006075_ref12","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.ridd.2012.07.029","article-title":"Patterns of multimorbidity in an older population of persons with an intellectual disability: results from the intellectual disability supplement to the Irish Longitudinal study on aging (IDS-TILDA)","volume":"34","author":"McCarron","year":"2013","journal-title":"Res Dev Disabil"},{"key":"S2056472423006075_ref18","unstructured":"18 \u00d6nder, H , Bek, Y . Use of generalized estimating equation in biological experiments. 4th International Conference on Information and Communication Technologies in Bio and Earth Sciences (Athens, Sept 2008). Hellenic Association for ICT in Agriculture, Food and Environment, 2008."},{"key":"S2056472423006075_ref36","doi-asserted-by":"crossref","DOI":"10.1002\/9781118897164","volume-title":"The Frith Prescribing Guidelines for People with Intellectual Disability","author":"Sabyasachi Bhaumik","year":"2015"},{"key":"S2056472423006075_ref3","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1111\/jar.12591","article-title":"Prevalence and patterns of antipsychotic use and their associations with mental health and problem behaviours among older adults with intellectual disabilities","volume":"32","author":"O'Dwyer","year":"2019","journal-title":"J Appl Res Intellect Disabil"},{"key":"S2056472423006075_ref17","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/(SICI)1521-4036(199806)40:2<115::AID-BIMJ115>3.0.CO;2-6","article-title":"The generalised estimating equations: an annotated bibliography","volume":"40","author":"Ziegler","year":"1998","journal-title":"Biometr J"},{"key":"S2056472423006075_ref11","volume-title":"Growing Older with an Intellectual Disability in Ireland 2011: First Results from the Intellectual Disability Supplement to the Irish Longitudinal Study on Ageing (IDS-TILDA)","author":"McCarron","year":"2011"},{"key":"S2056472423006075_ref38","unstructured":"38 Health Service Executive. National Framework for Medicines Management in Disability Services. HSE, 2021 (https:\/\/www.hse.ie\/eng\/services\/publications\/disability\/national-framework-for-medicines-management-in-disability-services.pdf)."},{"key":"S2056472423006075_ref8","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1136\/bmj.329.7463.414","article-title":"People with intellectual disabilities","volume":"329","author":"Cooper","year":"2004","journal-title":"BMJ"}],"container-title":["BJPsych Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S2056472423006075","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T06:53:46Z","timestamp":1706770426000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S2056472423006075\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,1]]},"references-count":38,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,3]]}},"alternative-id":["S2056472423006075"],"URL":"https:\/\/doi.org\/10.1192\/bjo.2023.607","relation":{},"ISSN":["2056-4724"],"issn-type":[{"value":"2056-4724","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,1]]},"assertion":[{"value":"Copyright \u00a9 The Author(s), 2024. Published by Cambridge University Press on behalf of Royal College of Psychiatrists","name":"copyright","label":"Copyright","group":{"name":"copyright_and_licensing","label":"Copyright and Licensing"}},{"value":"This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http:\/\/creativecommons.org\/licenses\/by\/4.0\/), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.","name":"license","label":"License","group":{"name":"copyright_and_licensing","label":"Copyright and Licensing"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}],"article-number":"e39"}}